Mountzios Giannis, Lampaki Sofia, Linardou Helena, Georgoulias Vassilis, Mavroudis Dimitrios, Anevlavis Stavros, Charpidou Andriani, Lykka Maria, Spyratos Dionysis, Sarris Evangelos G, Somarakis Alvertos, Papista Christina, Glentis Alexandros, Nikolaou Aristeidis, Paparepa Zoe, Papageorgiou Foteini, Syrigos Konstantinos N
Fourth Oncology Department and Clinical Trials Unit, Henry Dunant Hospital Center, Athens, Greece.
Pulmonary Department, General Hospital 'G. Papanikolaou', Aristotle University of Thessaloniki, Thessaloniki, Greece.
Future Oncol. 2025 Feb;21(4):447-462. doi: 10.1080/14796694.2024.2442295. Epub 2025 Jan 9.
The treatment landscape of non-metastatic non-small cell lung cancer (NM-NSCLC) is rapidly evolving with recent approvals of immunotherapies and targeted therapies.
This retrospective study included 202 adults diagnosed with NM-NSCLC between 1 January 2018 and 31 December 2020 primarily aiming to capture initial management strategies.
Most frequent treatment patterns among Stage I/II patients ( = 84) were surgery only (48.8%) and surgery with adjuvant chemotherapy (with/without RT; 42.9%). Among Stage III patients ( = 118), most frequent patterns were chemotherapy plus radiotherapy (44.9%) and chemotherapy only (18.6%); 58.6% of Stage IIIA patients underwent surgery (of these, 32.4% also received chemotherapy and radiotherapy).
Initial strategy was aligned with contemporary at that time European guidelines, setting a benchmark for understanding the future uptake of new therapies.
随着免疫疗法和靶向疗法最近获得批准，非转移性非小细胞肺癌（NM-NSCLC）的治疗格局正在迅速演变。
这项回顾性研究纳入了202名在2018年1月1日至2020年12月31日期间被诊断为NM-NSCLC的成年人，主要目的是了解初始治疗策略。
I/II期患者（n = 84）中最常见的治疗模式是单纯手术（48.8%）和手术联合辅助化疗（伴或不伴放疗；42.9%）。在III期患者（n = 118）中，最常见的模式是化疗加放疗（44.9%）和单纯化疗（18.6%）；58.6%的IIIA期患者接受了手术（其中32.4%还接受了化疗和放疗）。
初始策略与当时的当代欧洲指南一致，为理解新疗法的未来应用设定了基准。
